News & Updates

In the phase II VELO trial, third-line (3L) treatment with the anti-EGFR* monoclonal antibody (mAb) panitumumab and standard of care (SoC) improved progression-free survival (PFS) in patients with refractory RAS wild-type metastatic colorectal cancer (WT mCRC).

Pancreatic cancer, recognized as a silent yet potent malignancy, stands among the most lethal forms of cancer. Although ranking as the twelfth most prevalent cancer diagnosed globally, it claims the seventh highest fatality rate, with a disappointing 5 to 10 percent 5-year survival rate. [Available at https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosis Accessed on 30 August 2023]  According to the Global Cancer Observatory 2020 (Globocan) report by the WHO, Malaysia had 1,089 new cases of pancreatic cancer, resulting in 1,066 fatalities. Notably, the incidence was calculated at approximately two individuals per 100,000. 

Epidermal growth factor receptor (EGFR)-mothers against decapentaplegic homologue 7 (SMAD7)-Chimeric antigen receptor (CAR) T-cell therapy against nonsmall-cell lung cancer (NSCLC) is on a par with EGFR-dominant‒negative transforming growth factor (TGFbeta) receptor 2 (DNR)-CAR-T in terms of efficacy and resistance to negative TGFβ regulation, a study has shown.

Using 30 kcal/kg to predict energy requirements overestimates total energy expenditure (TEE) by 1.44 times in patients with colorectal cancer (CRC) in a controlled sedentary environment, as shown in a study. In addition, TEE is outside of the predicted requirement range for most.